Table 5.
Factors potentially associated with improvement of physical activity (Δ-steps). Results of multivariable regression analysis.
| Unstandardized Coefficients | Standardized Coefficients | t | P value | 95.0% Confidence Interval for B | |||
|---|---|---|---|---|---|---|---|
| B | Std. Error | Beta | Lower Bound | Upper Bound | |||
| (Constant) | −7,403.588 | 4,378.612 | −1.691 | 0.096 | −16,145.770 | 1,338.594 | |
| Type of heart failure | 426.845 | 581.195 | 0.087 | 0.734 | 0.465 | −733.548 | 1,587.239 |
| Change in LVEF | 7.474 | 29.654 | 0.032 | 0.252 | 0.802 | −51.731 | 66.679 |
| Wearing Time (hours) | 300.357 | 141.208 | 0.253 | 2.127 | 0.037 | 18.427 | 582.287 |
| Days carried | 13.830 | 6.518 | 0.251 | 2.122 | 0.038 | 0.816 | 26.845 |
| B-Blockers | 2,756.052 | 1,814.530 | 0.180 | 1.519 | 0.134 | −866.775 | 6,378.878 |
| ACEi | −2,094.027 | 1,765.064 | −0.370 | −1.186 | 0.240 | −5,618.091 | 1,430.037 |
| ARBs | −1,349.070 | 1,955.594 | −0.169 | −0.690 | 0.493 | −5,253.539 | 2,555.399 |
| Sacubitril/valsartan | −2,022.073 | 1,789.791 | −0.395 | −1.130 | 0.263 | −5,595.506 | 1,551.360 |
| MRAs | −442.009 | 801.970 | −0.066 | −0.551 | 0.583 | −2,043.194 | 1,159.176 |
| SGLT-2i | 50.226 | 598.536 | 0.010 | 0.084 | 0.933 | −1,144.789 | 1,245.241 |
Type of heart failure: ischemic vs. nonischemic; LVEF, left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; MRAs, Mineralocorticoid receptor antagonists, SGLT-2i, Sodium-glucose cotransporter-2 inhibitors.